Literature DB >> 1610966

Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women.

M G Lê1, P A Cabanes, V Desvignes, M F Chanteau, N Mlika, M F Avril.   

Abstract

We report the results of a case-control study designed to analyze the relationship between oral contraceptive use (OC) and the risk of cutaneous malignant melonama (MM) in 240 White women under the age of 45. Five French centers participated in the study between February 1982 and January 1987 for periods of eight to 54 months, depending on the center. Cases were 91 consecutive newly diagnosed patients with histologically verified MM. Each case was matched with one or two controls on year of birth, date of interview, and treatment center. Controls were 149 patients with either malignant or nonmalignant disease who came to the center for diagnosis and treatment. Odds ratios (OR) were estimated by multivariate analyses taking into account age at menarche, sunlight exposure, and skin characteristics. No significant relation was found between the risk of MM and the total duration of OC use, age at start of use, and elapsed time since the first OC use. However, when the analysis was restricted to women aged 30-40 years, i.e., those who were able to use OC for 10 years or more, or who had started OC use 15 years or more before the diagnosis, the risk of MM increased significantly with the duration of OC use (P = 0.03). A total of more than 4,000 hours of sunlight exposure, and menarche before the age of 14 also were found to increase significantly the risk of MM (OR = 5.4, 95 percent confidence interval [CI] = 1.6-18.3; and OR = 3.6, CI = 1.0-12.5, respectively).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1610966     DOI: 10.1007/bf00124252

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  19 in total

1.  The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation.

Authors:  R S SNELL; P G BISCHITZ
Journal:  J Invest Dermatol       Date:  1960-08       Impact factor: 8.551

2.  The impact of confounder selection criteria on effect estimation.

Authors:  R M Mickey; S Greenland
Journal:  Am J Epidemiol       Date:  1989-01       Impact factor: 4.897

3.  Estimation of multiple relative risk functions in matched case-control studies.

Authors:  N E Breslow; N E Day; K T Halvorsen; R L Prentice; C Sabai
Journal:  Am J Epidemiol       Date:  1978-10       Impact factor: 4.897

4.  Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use.

Authors:  S P Helmrich; L Rosenberg; D W Kaufman; D R Miller; D Schottenfeld; P D Stolley; S Shapiro
Journal:  J Natl Cancer Inst       Date:  1984-03       Impact factor: 13.506

5.  Oral contraceptive use and malignant melanoma.

Authors:  C Bain; C H Hennekens; F E Speizer; B Rosner; W Willett; C Belanger
Journal:  J Natl Cancer Inst       Date:  1982-04       Impact factor: 13.506

6.  Cutaneous melanoma in relation to exogenous hormones and reproductive factors.

Authors:  E A Holly; N S Weiss; J M Liff
Journal:  J Natl Cancer Inst       Date:  1983-05       Impact factor: 13.506

7.  [Estrogen and progesterone receptors in malignant melanoma, benign pigmented nevi and basocellular epithelioma].

Authors:  M F Avril; J C Delarue; M Prade
Journal:  Pathol Biol (Paris)       Date:  1985-01

8.  Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody.

Authors:  J L Flowers; H F Seigler; K S McCarty; J Konrath; K S McCarty
Journal:  Arch Dermatol       Date:  1987-06

9.  Oestrogen receptors in human malignant melanoma.

Authors:  R I Fisher; J P Neifeld; M E Lippman
Journal:  Lancet       Date:  1976-08-14       Impact factor: 79.321

10.  Malignant melanoma and oral contraceptive use among women in California.

Authors:  V Beral; S Ramcharan; R Faris
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640

View more
  8 in total

1.  Age at first birth and melanoma risk: a meta-analysis.

Authors:  Zhengyong Li; Mingjin Gu; Ying Cen
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Oral contraceptives and cancer. A review of the evidence.

Authors:  C La Vecchia; A Tavani; S Franceschi; F Parazzini
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

3.  Oral contraceptive use and risk of cutaneous malignant melanoma.

Authors:  J R Palmer; L Rosenberg; B L Strom; S Harlap; A G Zauber; M E Warshauer; S Shapiro
Journal:  Cancer Causes Control       Date:  1992-11       Impact factor: 2.506

4.  Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors.

Authors:  J Westerdahl; H Olsson; A Måsbäck; C Ingvar; N Jonsson
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

5.  Oral contraceptive use and risk of melanoma in premenopausal women.

Authors:  D Feskanich; D J Hunter; W C Willett; D Spiegelman; M J Stampfer; F E Speizer; G A Colditz
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

6.  A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use.

Authors:  M R Karagas; T A Stukel; J Dykes; J Miglionico; M A Greene; M Carey; B Armstrong; J M Elwood; R P Gallagher; A Green; E A Holly; C S Kirkpatrick; T Mack; A Østerlind; S Rosso; A J Swerdlow
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

Review 7.  Exogenous Hormone Factors in Relation to the Risk of Malignant Melanoma in Women: A Systematic Review and Meta-Analysis.

Authors:  Manuela Chiavarini; Giulia Naldini; Irene Giacchetta; Roberto Fabiani
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

Review 8.  Estrogen Receptors and Melanoma: A Review.

Authors:  Emi Dika; Annalisa Patrizi; Martina Lambertini; Nicholas Manuelpillai; Michelangelo Fiorentino; Annalisa Altimari; Manuela Ferracin; Mattia Lauriola; Enrica Fabbri; Elena Campione; Giulia Veronesi; Federica Scarfì
Journal:  Cells       Date:  2019-11-19       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.